Understand the source comparison
FOXO4-DRI vs NAD+: What Each Actually Does | Real Peptides
A 2017 study published in Cell found that FOXO4-DRI restored fur density, renal function, and physical fitness in naturally aged mice within weeks. Results so dramatic that the lead researcher at Erasmus University Medical Center called them 'unprecedented' fo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- A 2017 study published in Cell found that FOXO4-DRI restored fur density, renal function, and physical fitness in naturally aged mice within weeks. Results so dramatic that the lead researcher at Erasmus University Medical Center called them 'unprecedented' for a single intervention. What the study didn't claim: that FOXO4-DRI and NAD+ work through the same mechanism or target the same cellular dysfunction.
- Our team has reviewed this across hundreds of research inquiries. The pattern is consistent every time: people discover both compounds in longevity literature and assume they're interchangeable or competing options. They're not. One removes dysfunctional cells that have stopped dividing but refuse to die. The other powers the metabolic machinery that keeps functional cells alive. Understanding the difference between FOXO4-DRI and NAD+ means understanding what each compound actually does at the cellular level. And why asking which is 'better' misses the point entirely.
- What's the difference between FOXO4-DRI and NAD+?
- FOXO4-DRI is a synthetic peptide that disrupts the interaction between FOXO4 and p53 proteins inside senescent cells, triggering apoptosis selectively in cells that have entered permanent growth arrest. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in redox reactions across all living cells, supporting mitochondrial function, DNA repair, and sirtuin activity. The difference is categorical: FOXO4-DRI eliminates specific dysfunctional cells, while NAD+ sustains metabolic function in healthy cells. They address entirely different aspects of aging biology.
- Most explanations stop at 'senolytic versus metabolic support' without explaining why that distinction matters clinically. FOXO4-DRI works through targeted cell death. It doesn't improve the function of senescent cells, it removes them from tissue. NAD+ works through metabolic enhancement. It doesn't eliminate damaged cells, it optimizes energy production in cells that are still functional. This article covers exactly how each mechanism operates, what research contexts each compound appears in, and why the longevity research community doesn't frame them as competing interventions.